White Rabbit Ventures

Strategic deployment of capital into the emerging space of psychedelic therapeutics. 

White Rabbit Ventures focuses on Asia-Pacific investment opportunities in the psychedelic therapeutic space, leveraging Australia’s strong scientific research capabilities and biotech commercialisation record.

eberhard-grossgasteiger-Md2F2di-R68-unsp
 

White Rabbit Ventures comprises three separate, but symbiotic, streams.

Venture Fund

Utilising its industry expertise and networks, White Rabbit Ventures will invest in and manage a portfolio of companies aiming to develop and commercialise psychedelic compounds, protocols and complementary technologies.

Incubator

Through collaboration with research partners, principally located in Australia, White Rabbit Ventures will build an IP portfolio focusing on the development of psychedelic compounds into licensed pharmaceutical medicines. White Rabbit Ventures will leverage its networks and experience within corporate advisory, governance and entrepreneurship to successfully commercialise and scale early-stage projects.

Clinics

White Rabbit Ventures will invest in fully integrated therapy and wellness clinics incorporating psychedelic-assisted therapies as part of a broader multidisciplinary approach to healing.

mushroom-25_edited_edited.jpg

Mental health problems have risen dramatically in recent decades, now accounting for approximately 7% of the worldwide disease burden, a near-doubling in incidence since 1990. The Lancet Commission Report of 2017 found that mental health disorders could cost the global economy up to US$16 trillion between 2010 and 2030 if these problems remain unaddressed.

 

Psychedelic-based medicines have the potential to revolutionise the treatment of mental health conditions – including depression, anxiety, tobacco and alcohol dependence, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) – as well as other conditions such as Alzheimer’s Disease.

 

Despite the substantial size of the addressable market, “Big Pharma” has not fully engaged with the emerging opportunity in psychedelic therapeutics, and there exists an opportunity for specialist players with a deep knowledge of the industry to capitalise on their early mover advantage to disrupt the market for mental health.

 

White Rabbit Ventures unites unparalleled relationships and experience within the nascent psychedelic therapeutic space with a strong track record in deal execution and asset management.

About us

 

Contact Us

Thanks for submitting!